explore -WSS

explore

author：hotspot 2025-10-01 00:17:03 - browse：86645

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Questions and answers about ramping up H5N1 bird flu vaccine

WSS

Despite FDA concern, risk that CAR

Will the market for weight loss drugs really reach $100 billion?

Flagship Pioneering launches a new biotech in two countries

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

FDA investigates CAR

hotspot

explore

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

H5N1 virus can be tracked in retail milk, scientists say

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Making the case for fair compensation in clinical trials

New air purifier tech could be key to improving indoor air quality

Will the market for weight loss drugs really reach $100 billion?

Alkermes shareholders re

Investigation reveals sickle cell patients pressured into sterilizations

Psychedelics group wrestles with new pharma identity

Flagship Pioneering launches a new biotech in two countries

knowledge

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

The EPA's new lead rule: How one expert crunched the numbers

BIO selects John Crowley as new CEO

Reports of telehealth's death have been greatly exaggerated

Biogen joins immunology wave with $1.15 billion acquisition of HI

Fentanyl is making it harder to start addiction treatment

leisure time

focus

hotspot

focus